The debate portion of today's booster meeting starts off with a bang. FDA's Krause is tearing apart Pfizer's data. Study showing 61% efficacy actua

The debate portion of today's booster meeting starts off with a bang. FDA's Krause is tearing apart Pfizer's data. Study showing 61% efficacy actua